A phase III clinical study of combination therapy with elbasvir (EBR) and grazoprevir (GZR) was conducted in Japan, and the additive therapeutic effects were obtained. In this study, we report safety and efficacy of EBR/GZR combination therapy in a real-world practice.
Alba Sparacino, Gabriele Di Maria, Marco Vaccaro, Giuseppe Cabibbo, Calogero Cammà, María Reig, Robin Kate Kelley, Amit G. Singal, Ahmed O. Kaseb, Masatoshi Kudo, Lorenza Rimassa, David J. Pinato, Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li, Marta Fortuny, Najib Ben Khaled, Massimo Iavarone, Hidenori Toyoda, Ilario Giovanni Rapposelli, Andrea Casadei‐Gardini, Caterina Vivaldi, Susanna V. Ulahannan, Haripriya Andanamala, Bernhard Scheiner, Matthias Pinter, Elena Orlandi, Claudia Angela Maria Fulgenzi, Giulia Francesca Manfredi,
Discussion(0)
No comments yet. Be the first to comment.